Group 1 - The pet economy sector experienced a decline of 0.89% compared to the previous trading day, with Yong'an Pharmaceutical leading the drop [1] - On the same day, the Shanghai Composite Index closed at 4134.02, up 0.05%, while the Shenzhen Component Index closed at 14283.0, up 0.86% [1] - The net capital outflow from the pet economy sector amounted to 377 million yuan, while retail investors saw a net inflow of 312 million yuan [1] Group 2 - The main capital flow in the pet economy sector showed a net outflow of 377 million yuan from institutional investors, with a net inflow of 65.44 million yuan from speculative funds [1] - Detailed capital flow data for individual stocks in the pet economy sector is available in the accompanying table [1]

Financial Performance - The company expects a significant decline in net profit for 2025, projecting a decrease of 56.21% to 70.56%, with estimated profits ranging from 18.19 million to 27.05 million yuan, primarily due to intense competition in the taurine market [2][4] - The company's stock price has experienced considerable volatility, with a reported cumulative decline of 8.00% as of February 1, 2026, and a net outflow of 50.26 million yuan in principal funds [5] Operational Developments - The company signed an annual equipment processing framework agreement with an affiliate, Hubei Yongbang Engineering Technology Co., Ltd., with a total transaction amount not exceeding 20 million yuan, valid for one year [3] Industry Environment - The taurine market is facing a downturn and fierce competition, which is likely to continue impacting the company's performance in 2026 [4] - The pharmaceutical and biotechnology sector is supported by policy initiatives, such as accelerated reviews for innovative drugs, and is driven by an aging population, although individual stock performance varies [4]

Core Viewpoint - Yong'an Pharmaceutical reported that as of January 30, 2026, the number of shareholders reached 49,230 [2] Summary by Category - Company Information - Yong'an Pharmaceutical has a total of 49,230 shareholders as of the specified date [2] - Industry Context - The information reflects the company's shareholder engagement and potential interest in the pharmaceutical sector [2]

Core Viewpoint - The company has approved the use of up to RMB 750 million of its own funds for entrusted wealth management, with a focus on low-risk financial products to enhance capital efficiency and profitability [1][18]. Group 1: Wealth Management Products Overview - On February 5, 2026, the company invested RMB 20 million in a wealth management product from Changjiang Securities, with an expected annualized return of 3.4% plus excess returns [4][18]. - On February 3, 2026, the company invested RMB 10 million in a wealth management product from Huatai Securities, with an expected annualized return of 2.15% to 3.2% [5][18]. - On January 27, 2026, the company invested RMB 20 million in a wealth management product from Founder Securities, with an expected annualized return of 4.0% plus excess returns [6][18]. - On January 21, 2026, the company invested RMB 30 million in a wealth management product from Bank of China, with an expected annualized return linked to the seven-day notice deposit rate [8][18]. - On January 12, 2026, the company invested RMB 20 million in a wealth management product from CITIC Securities, with an expected annualized return of 2.35% [10][18]. - On January 9, 2026, the company invested RMB 30 million in a wealth management product from Changjiang Securities, with an expected annualized return of 2.6% plus excess returns [12][18]. - On December 12, 2025, the company invested RMB 30 million in a wealth management product from Changjiang Securities, with an expected annualized return of 2.5% plus excess returns [15][18]. Group 2: Risk Management and Compliance - The company has established a strict management system for entrusted wealth management, including principles, approval authority, decision-making processes, and risk control measures [17]. - The finance department is responsible for daily management, investment control, and auditing of entrusted wealth management activities [17]. - Independent directors and the audit committee have the authority to inspect the entrusted wealth management activities [17]. Group 3: Financial Impact - The company maintains a healthy cash flow and aims to use part of its idle funds for low-risk wealth management to improve capital efficiency and profitability, benefiting shareholders [18]. - As of the announcement date, the company has approximately RMB 612.4 million in outstanding wealth management products, accounting for 30.72% of the latest audited net assets, which is within the authorized limit [18].

证券代码：002365 证券简称：永安药业 公告编号：2026-09 潜江永安药业股份有限公司 关于购买理财产品的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日、2025 年 6 月 24 日分别召开了第七届董事会第六次临时会议及 2024 年年度股东会，审 议通过了《关于使用自有资金进行委托理财的议案》，同意公司及子公司总计使 用最高额度不超过（含）人民币 7.5 亿元的自有资金进行委托理财。上述额度 可滚动使用，有效期自股东会审议通过之日起不超过 12 个月，并授权公司管理 层具体实施相关事宜。公司根据上述决议，择机购买了相关理财产品，现将有关 情况公告如下： （2）期货和衍生品类资产：国债期货。 本计划属于固定收益类集合资产管理计划，产品通过主要投资于上述资产构 建的投资组合，符合《运作规定》组合投资的要求。 本计划可参与债券正回购，债券回购为提升组合收益提供了可能，但也存在 一定的风险。 如法律法规或中国证监会允许本计划投资其他品种的，管理人、托管人协商 一致并履 ...

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) forecasts a significant decline in its 2025 annual performance, with net profit attributable to shareholders expected to drop by 56.21% to 70.56% compared to the previous year [1] Financial Performance - The projected net profit for 2025 is between 18.19 million yuan and 27.05 million yuan [1] - The net profit after deducting non-recurring gains and losses is expected to be a loss of 1.55 million yuan to 2.88 million yuan, compared to a profit of 26.76 million yuan in the same period last year [1] - Basic earnings per share are estimated to be between 0.0617 yuan and 0.0918 yuan [1] Market Conditions - The decline in performance is primarily attributed to a sluggish market environment and intense competition in the taurine market [1] - Both the production and sales volume, as well as the selling price of the main product taurine, have decreased compared to the same period last year [1]

Group 1 - The company expects a significant decline in net profit for the year 2025, projecting a decrease of over 50% compared to the previous year [1][2] - The performance forecast period is from January 1, 2025, to December 31, 2025, with the net profit expected to be positive but substantially lower [1] - The decline in performance is attributed to a sluggish market and intense competition in the taurine market, leading to a decrease in both the sales volume and prices of the main product, taurine [2] Group 2 - The performance forecast has not been audited by the accounting firm, and the final financial data will be confirmed in the annual report for 2025 [1][3] - Initial communication regarding the performance forecast has taken place with the annual audit accounting firm, but specific data will depend on the final audit results [1][3]

Core Viewpoint - Yong'an Pharmaceutical is expected to report a significant decline in net profit for the year 2025, with projections indicating a decrease of 56.21% to 70.56% compared to the previous year [1] Financial Performance - The estimated net profit attributable to shareholders for 2025 is projected to be between 18.19 million and 27.05 million yuan [1] - The estimated net profit after deducting non-recurring gains and losses is expected to be between -2.88 million and -1.55 million yuan [1] Market Conditions - The company's performance is anticipated to decline sharply due to a sluggish market environment [1] - The competition in the taurine market has intensified, leading to a decrease in both the production and sales prices of the company's main product, taurine [1]

Financial Performance - The company expects a net profit of approximately 18.19 million yuan, representing a decline of 70.56% compared to the same period last year [5]. - The net profit after deducting non-recurring losses is projected to be -2.88 million yuan, a decrease of 110.77% year-on-year [5]. - Basic earnings per share are estimated at 0.0617 yuan, down from 0.2107 yuan in the previous year [5]. - The significant decline in performance is attributed to a sluggish market and intensified competition in the taurine market, leading to decreased production and sales prices [7]. - The company reported a total revenue of 67.76 million yuan for the previous year, indicating a significant drop in expected performance [5]. Audit and Forecast - The financial data presented is preliminary and subject to final audit results, with the annual audit currently in progress [6]. - The company has communicated with the auditing firm regarding the performance forecast, but specific financial data will be confirmed in the 2025 annual report [6]. - Investors are advised to be aware of investment risks associated with the preliminary nature of the performance forecast [8]. - The performance forecast period is from January 1, 2025, to December 31, 2025 [3]. Information Disclosure - The company emphasizes the importance of accurate information disclosure and the absence of misleading statements [2].

Core Viewpoint - Yong'an Pharmaceutical announced an expected decline in net profit attributable to shareholders for 2025, forecasting a range of 18.19 million to 27.05 million yuan, representing a decrease of 56.21% to 70.56% compared to the previous year [1] Financial Performance - The net profit after deducting non-recurring gains and losses is projected to be between -2.88 million and -1.55 million yuan, indicating a decline of 105.80% to 110.77% year-on-year [1] - The decline in performance is primarily attributed to a sluggish market and intense competition in the taurine market, leading to a decrease in both the production and sales prices of the main product, taurine [1]